Morgan Stanley Selecta Biosciences Inc Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Oct 17, 2024	BUY	$0.62 - $0.85 $136,984 - $187,800	220,942 New	220,942 $185,000
Q1 2024 Aug 16, 2024	SELL	$0.62 - $0.85 $39,644 - $54,351	-63,943 Reduced 22.45%	220,942 $185,000
Q1 2024 May 15, 2024	SELL	$0.62 - $0.85 $39,644 - $54,351	-63,943 Reduced 22.45%	220,942 $185,000
Q4 2023 Aug 16, 2024	BUY	$0.67 - $1.35 $190,872 - $384,594	284,885 New	284,885 $196,000
Q4 2023 Feb 13, 2024	BUY	$0.67 - $1.35 $75,329 - $151,783	112,432 Added 65.2%	284,885 $196,000
Q3 2023 Nov 15, 2023	SELL	$1.02 - $1.23 $82,597 - $99,602	-80,978 Reduced 31.95%	172,453 $182,000
Q2 2023 Aug 14, 2023	SELL	$1.04 - $1.4 $15,549 - $20,931	-14,951 Reduced 5.57%	253,431 $283,000
Q1 2023 May 15, 2023	BUY	$1.15 - $1.89 $143,744 - $236,240	124,995 Added 87.17%	268,382 $373,000
Q4 2022 Feb 14, 2023	BUY	$0.96 - $1.6 $49,883 - $83,139	51,962 Added 56.84%	143,387 $162,000
Q3 2022 Nov 14, 2022	SELL	$1.33 - $2.6 $1.11 Million - $2.18 Million	-837,682 Reduced 90.16%	91,425 $150,000
Q2 2022 Oct 27, 2022	BUY	$0.67 - $1.4 $68,901 - $143,973	102,838 Added 12.45%	929,107 $1.22 Million
Q2 2022 Aug 15, 2022	BUY	$0.67 - $1.4 $68,901 - $143,973	102,838 Added 12.45%	929,107 $1.22 Million
Q1 2022 Oct 27, 2022	SELL	$1.23 - $3.31 $126,490 - $340,393	-102,838 Reduced 11.07%	826,269 $1.02 Million
Q1 2022 May 13, 2022	SELL	$1.23 - $3.31 $569,611 - $1.53 Million	-463,099 Reduced 35.92%	826,269 $1.02 Million
Q4 2021 Feb 14, 2022	BUY	$2.89 - $4.43 $2.32 Million - $3.56 Million	804,353 Added 165.84%	1,289,368 $4.2 Million
Q3 2021 Nov 15, 2021	BUY	$3.36 - $4.62 $1.63 Million - $2.24 Million	485,015 New	485,015 $2.02 Million

Others Institutions Holding SELB

# of Institutions

Shares Held

4.67M

Call Options Held

Put Options Held

View Full List

About SELECTA BIOSCIENCES INC

Ticker SELB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 152,712,992
Market Cap $128M
Description
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. I...

More about SELB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account